Search clinical trials for: GDC-0941

Total 1879 results

National Cancer Institute (NCI)

Completed

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Adult Medulloblastoma

United States
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom, France
Genentech, Inc.

Completed

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Endometrial Carcinoma

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors

Solid Cancers

Spain
Genentech, Inc.

Completed

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

Healthy Volunteers

United States
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Metastatic Prostate Cancer | Advanced Prostate Cancer

Korea, Republic of, United States, Australia
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia
Genentech, Inc.

Completed

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

United States, Germany, Canada
Genentech, Inc.

Completed

A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants

Healthy Volunteer

United Kingdom
Lisa Bax
Roche Pharma AG; Genentech, Inc.

Terminated

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) (HIPPoS)

Pancreatic Ductal Adenocarcinoma

United Kingdom
Genentech, Inc.

Completed

Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810

Healthy Volunteer

United Kingdom
Genentech, Inc.

Approved for marketing

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Basal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central Chondrosarcoma

France
Lupin Research Inc

Completed

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Bacterial Vaginoses

United States
Genentech, Inc.

Completed

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Hepatic Insufficiency

United States
Genentech, Inc.

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

Healthy Volunteers

United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

Healthy Volunteer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Genentech, Inc.

Completed

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Hungary, Australia, Brazil, Canada, Spain, Germany, United Kingdom, Chile, Israel, Italy, Netherlands, Argentina, Ukraine, Russian Federation
Genentech, Inc.

Completed

A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

Healthy Volunteer

United States
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Recurrent Childhood Medulloblastoma

United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Argentina, Brazil, Mexico, United Kingdom, Chile, Germany
Genentech, Inc.

Terminated

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Urticaria

United States
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

Recurrent Childhood Medulloblastoma

United States
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Renal Anemia in Non-dialysis Chronic Kidney Disease

China
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Genentech, Inc.

Completed

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

Healthy Volunteers
Hoffmann-La Roche

Completed

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Solid Tumor, Unspecified, Adult

United States
Genentech, Inc.

Completed

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Basal Cell Carcinoma

Australia, France, United States, Germany, Belgium, United Kingdom
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Endometriosis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Active Crohn's Disease

Crohn's Disease
Hoffmann-La Roche

Recruiting

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA)

Endometrial Cancer

United States, Canada, Italy, Poland
NYU College of Dentistry
Genentech, Inc.

Completed

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors (KCOT)

Keratocystic Odontogenic Tumor

United States
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
Genentech, Inc.
National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...

Completed

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects

Healthy Subjects

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

Type 2 Diabetes Mellitus
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)

Solid Tumors

United States, Spain, Germany, France, Israel, Italy, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
Genentech, Inc.

Withdrawn

A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants

Healthy Volunteer

United Kingdom

3

Subscribe